triplizumab
Showing 1 - 1 of 1
Bladder Cancer Trial in Nanjing (RC48-ADC, Triplizumab)
Not yet recruiting
- Bladder Cancer
- RC48-ADC
- Triplizumab
-
Nanjing, Jiangsu, ChinaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University
Aug 20, 2021